SPECIAL NOTICE
A -- PHASE 3 EFFICACY TESTING OF THE HIV VACCINE, AD26.MOS4.HIV + GP140 PROTEINS
- Notice Date
- 2/27/2019
- Notice Type
- Synopsis
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Attn: MCMR-AAA 820 Chandler Street Frederick, MD 21702-5014 MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-19-RFI-JD4-06
- Response Due
- 3/19/2019
- Point of Contact
- Jamie Diggs, Contract Specialist, Phone 3016192663
- E-Mail Address
-
jamie.l.diggs.civ@mail.mil
- Small Business Set-Aside
- N/A
- Description
- Pharmaceutical Systems Program Management Office of the U.S. Army Medical Materiel Development Activity has a requirement for an FDA-approved Ad26.Mos4.HIV + gp140 proteins HIV vaccine. The Army is collaborating in the development of a vaccine to prevent infection from HIV. The Army wishes to continue supporting the vaccine development effort during its Phase 3 effectiveness testing. This will be a global study in Europe and the Americas, and the Army will cost-share study activities required to conduct the Phase 3 efficacy testing. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (27-FEB-2019); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-19-RFI-JD4-06/listing.html)
- Record
- SN05234650-F 20190301/190227230026 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |